1-5 of 5
anal fissure
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Franck E Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnès Guerci-Bresler, MD PhD, Aude Charbonnier, MD PhD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD PhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, MD PhD, Denis Guyotat, MD PhD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Eric Deconinck, MD PhD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Alexandre Deloire, CRA, Stephane Morisset, BioStat, Madeleine Etienne, CRA, Delphine Rea, MD, Stephanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 494.
https://doi.org/10.1182/blood-2019-123674
Published: 2019
Journal Articles

Phase 2 Trial of Single Agent Gedatolisib (PF-05212384), a Dual PI3K/mTOR Inhibitor, for Adverse Prognosis and Relapse/Refractory AML: Clinical and Transcriptomic Results

Jacques Vargaftig, MD PhD, Hassan Farhat, MD, Lionel Ades, MD PhD, Adrien Briaux, Camille Benoist, Isabelle Turbiez, Norbert Vey, MD PhD, Sylvie Glaisner, MD, Céline Callens, PharmD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5233.
https://doi.org/10.1182/blood-2018-99-117485
Published: 2018
Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Franck Emmanuel Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MDPhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD PhD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, MD, Martine Gardembas, MD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Verane Schwiertz, PharmD, Stephane Morisset, Stat, Madeleine Etienne, CRA, Delphine Rea, MD PhD, Stephanie Dulucq, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 899.
https://doi.org/10.1182/blood.V130.Suppl_1.899.899
Published: 2017
Journal Articles

Phase II Study Of The c-MET Inhibitor ARQ 197 (Tivantinib) In Patients With Relapsed Or Relapsed/Refractory Multiple Myeloma (RRMM)

Robert Z. Orlowski, M.D., Ph.D, Shadia Zaman, Ph.D., Sheeba K. Thomas, M.D., Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, MD, Ashley N. Holloway, R.N., Veerabhadran Baladandayuthapani, Ph.D., Heather Yan Lin, Ph.D., Min Fu, Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha Gandhi, PhD
Journal: Blood
Blood (2013) 122 (21): 1953.
https://doi.org/10.1182/blood.V122.21.1953.1953
Published: 2013
Journal Articles

Phase II Study of the c-Met Inhibitor ARQ 197 (Tivantinib) in Patients with Relapsed Multiple Myeloma.

Stephan Joseph Dorkhom, D.O., Shadia Zaman, Ph.D., Sheeba K. Thomas, MD, Raymond Alexanian, M.D., Jatin J. Shah, M.D., Donna M. Weber, M.D., Michael Wang, M.D., Martha L. Anderson, R.N., Veerabhadran Baladandayuthapani, Ph.D., Yan Heather Lin, Ph.D., Min Fu, Ph.D., Christine M. Stellrecht, Ph.D., Claudia Morales de Partovi, B.S., Varsha V. Gandhi, Ph.D., Robert Z. Orlowski, M.D., Ph.D.
Journal: Blood
Blood (2012) 120 (21): 2976.
https://doi.org/10.1182/blood.V120.21.2976.2976
Published: 2012